A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
320 patients around the world
Available in Mexico, United States
This trial is a 6-month, randomized, double-blind, controlled, dose-ranging trial of ENV-101
in two parallel cohorts of adult patients with lung fibrosis: idiopathic pulmonary fibrosis
(IPF) and progressive pulmonary fibrosis (PPF). Patients are allowed to continue treatment
with approved standard of care (e.g., nintedanib, pirfenidone) during the trial. Patients
will be randomized to one of 3 dose levels of ENV-101 or placebo at baseline. The objectives
of this trial are to characterize the efficacy, antifibrotic activity, and safety of ENV-101
to select the Phase 3 dose of ENV-101 in each indication.
